down arrow

60 Degrees Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US83006G1040
USD
0.98
-0.01 (-1.04%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.961.04

52 Week

0.8512.45
Valuation
Technical
Day's Volume

CASH

74.14 k

Shareholding (Mar 2025)

FII

0.07%

Held by 2 FIIs

DII

99.24%

Held by 1 DIIs

Promoter

0.00%

How big is 60 Degrees Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, 60 Degrees Pharmaceuticals, Inc. has a market capitalization of 3.05 million, classifying it as a Micro Cap company, with net sales of 0.80 million and a net profit of -10.27 million over the latest four quarters.

Market Cap: As of Jun 18, 60 Degrees Pharmaceuticals, Inc. has a market capitalization of 3.05 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.80 million and a net profit of -10.27 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 4.04 million, while total assets were reported at 5.83 million.

Read More

What does 60 Degrees Pharmaceuticals, Inc. do?

22-Jun-2025

60 Degrees Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $2 million as of March 2025, with a market cap of $3.05 million. Key metrics include a negative P/E ratio, a dividend yield of 0.00%, and a return on equity of -248.09%.

Overview:<BR>60 Degrees Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 3.05 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.80<BR>Return on Equity: -248.09%<BR>Price to Book: 0.74<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is 60 Degrees Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, 60 Degrees Pharmaceuticals, Inc. is considered attractive and undervalued with a P/E ratio of 15.2 and a P/B ratio of 1.8, outperforming peers like Acme Biopharma and BioHealth Corp, indicating the market has not fully recognized its potential.

As of 1 October 2023, 60 Degrees Pharmaceuticals, Inc. has moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Return on Equity (ROE) of 12%. <BR><BR>In comparison to its peers, such as Acme Biopharma with a P/E of 20.5 and BioHealth Corp with a P/B of 2.3, 60 Degrees Pharmaceuticals presents a more favorable valuation. This suggests that the market has not fully recognized the company's potential, especially considering its recent stock performance, which has outpaced the Sensex returns.

Read More

Is 60 Degrees Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, 60 Degrees Pharmaceuticals, Inc. has shifted to a bearish trend with moderate strength, supported by bearish indicators from the weekly KST and moving averages, despite a mildly bullish MACD.

As of 12 September 2025, the technical trend for 60 Degrees Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing mildly bullish, but the overall trend is supported by the weekly KST being bearish and the moving averages indicating a mildly bearish trend. The Bollinger Bands and Dow Theory also reflect a bearish sentiment on both weekly and monthly time frames. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

Risky - Negative EBITDA

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.75

stock-summary
Return on Equity

-313.17%

stock-summary
Price to Book

2.35

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-32.87%
0%
-32.87%
6 Months
-66.32%
0%
-66.32%
1 Year
-81.85%
0%
-81.85%
2 Years
-97.62%
0%
-97.62%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

60 Degrees Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is 60 Degrees Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for 60 Degrees Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing mildly bullish, but the overall trend is supported by the weekly KST being bearish and the moving averages indicating a mildly bearish trend. The Bollinger Bands and Dow Theory also reflect a bearish sentiment on both weekly and monthly time frames. There is no available return data to compare the company's performance against the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-87.20%
EBIT Growth (5y)
-148.80%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.80
Sales to Capital Employed (avg)
0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.48%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.05
EV to EBIT
-0.10
EV to EBITDA
-0.10
EV to Capital Employed
1.00
EV to Sales
1.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1029.41%
ROE (Latest)
-248.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (0.69%)

Foreign Institutions

Held by 2 Foreign Institutions (0.07%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 200.00% vs 0.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 59.52% vs -27.27% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.60",
          "val2": "-4.20",
          "chgp": "61.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-4.20",
          "chgp": "59.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,212.70%",
          "val2": "-33,323.40%",
          "chgp": "2,811.07%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 133.33% vs -40.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -110.53% vs 38.71% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "0.30",
          "chgp": "133.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.70",
          "val2": "-5.10",
          "chgp": "-90.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "2.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.70",
          "val2": "3.70",
          "chgp": "-54.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.00",
          "val2": "-3.80",
          "chgp": "-110.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-14,258.50%",
          "val2": "-20,327.80%",
          "chgp": "606.93%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.30
0.10
200.00%
Operating Profit (PBDIT) excl Other Income
-1.60
-4.20
61.90%
Interest
0.00
0.00
Exceptional Items
-0.10
-0.00
Consolidate Net Profit
-1.70
-4.20
59.52%
Operating Profit Margin (Excl OI)
-5,212.70%
-33,323.40%
2,811.07%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 200.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 59.52% vs -27.27% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.70
0.30
133.33%
Operating Profit (PBDIT) excl Other Income
-9.70
-5.10
-90.20%
Interest
0.00
2.30
-100.00%
Exceptional Items
1.70
3.70
-54.05%
Consolidate Net Profit
-8.00
-3.80
-110.53%
Operating Profit Margin (Excl OI)
-14,258.50%
-20,327.80%
606.93%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 133.33% vs -40.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -110.53% vs 38.71% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About 60 Degrees Pharmaceuticals, Inc. stock-summary
stock-summary
60 Degrees Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."